CDC Updates COVID-19, Influenza Vaccine Recommendations for 2024-2025 Respiratory Virus Season
Individuals 6 months and older should receive updated COVID-19 and influenza vaccines for the 2024-2025 respiratory virus season, the agency recommended.
Prevalence of Chronic HTN During Pregnancy in US: Daily Dose
Your daily dose of the clinical news you may have missed.
Seen in the ED: Popcorn Kernel
After performing a back blow maneuver on her 10-month-old daughter to dislodge a popcorn kernel, a mother arrives at the ED with the child in distress. What happened?
ACIP Revises Recommendation for Adult RSV Vaccination
The committee endorsed a universal recommendation for a single lifetime dose of RSV vaccine for adults aged ≥75 years and a risk-based recommendation for those aged 60 to 74 years.
SECURE-T2D: Automated Insulin Delivery System Reduced A1c in Adults with Type 2 Diabetes
ADA 2024. Adults started on the Omnipod 5 AID system had an A1c reduction from 8.2% at baseline to 7.4% at 13 weeks, researchers report.
Racial Disparities in Cardiovascular Disease Outcomes: Daily Dose
FDA Gives Green Light to Ensifentrine for Maintenance Treatment of COPD in Adults
The dual PDE3/PDE4 inhibitor is the first inhaled product with a novel mechanism of action approved for COPD in 2 decades and is delivered via standard jet nebulizer.
One-Quarter of Adults with Difficult-to-Control T2D have Hypercortisolism, According to New Data
ADA 2024. Adults using more antihypertensive medications had higher odds for hypercortisolism, according to new data from the CATALYST phase 4 study.
Dapagliflozin Approved for Treatment of T2D in Children: Daily Dose
5 Questions on the ADA 2024 Standards of Care in Diabetes
This quick quiz tests what you know about updates to the 2024 ADA standards of care, which include guidance on antiobesity drugs and managing comorbid chronic disease.
Older US Adults Without CVD Still Using Aspirin for Primary Prevention
Nearly one-third of US adults aged 60 years and older continue to take daily aspirin despite published evidence recommending against use in the absence of CVD.
FLOW Trial: Semaglutide Lowers Risk for Major Kidney Disease, CV Events and Death Regardless of SGLT-2i Use
ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.
Sugar Substitute Raises Risk of Major Adverse Cardiovascular Events: Daily Dose
SURMOUNT-OSA: Tirzepatide Improves Sleep Apnea Symptoms, CV Outcomes in Adults with OSA and Obesity
ADA 2024. Adults with OSA and obesity receiving tirzepatide had improvements in sleep apnea severity and systolic blood pressure compared to placebo.
Global Prevalence of T1D Rising in Older Adults: Daily Dose
CGM Data May Enhance Prediction of Risk for Type 1 Diabetes in Those with Early Stage Disease
ADA 2024. The risk of progression to stage 3 type 1 diabetes may be better predicted using a combination of patient and CGM data, a new study suggests.
Pemvidutide Preserves Lean Mass With Weight Loss of Nearly 16%: MOMENTUM Phase 2 Trial
ADA 2024. MOMENTUM trial findings presented at the ADA yesterday showed 78.1% of weight loss attributable to loss of fat vs lean mass in adults with overweight or obesity.
After ACS, Long-Term Lipid Management for FH Suboptimal in Women Compared to Men
Fiver years after ACS, a new study shows women are less likely to be on lipid lowering therapy and to meet LCL-C target levels than men.
USPSTF Recommends Intensive Behavioral Interventions for Children, Teens with High BMI
The grade B recommendation (moderate certainty) targets youth aged 6 years and older with a BMI at or above the 95th percentile for age and sex.
WHO Issues Medical Product Alert for Counterfeit Semaglutide
Three falsified batches of semaglutide (Ozempic) are in circulation, posing risks for ineffective treatment due to incorrect dosing, contamination, and use of unknown ingredients, warned WHO.
